Atherosclerosis Drugs

Atherosclerosis Drugs

Global Atherosclerosis Drugs Market to Reach US$25.3 Billion by 2030

The global market for Atherosclerosis Drugs estimated at US$20.6 Billion in the year 2023, is expected to reach US$25.3 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Antiplatelet & Anticoagulants, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$13.2 Billion by the end of the analysis period. Growth in the ACE Inhibitors segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.6 Billion While China is Forecast to Grow at 5.5% CAGR

The Atherosclerosis Drugs market in the U.S. is estimated at US$5.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.0 Billion by the year 2030 trailing a CAGR of 5.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Atherosclerosis Drugs Market - Key Trends and Drivers Summarized

Atherosclerosis is a chronic condition characterized by the accumulation of plaque within the arteries, leading to narrowed and stiffened artery walls which can impede blood flow or lead to thrombosis. Atherosclerosis is a principal cause of cardiovascular diseases (CVDs), such as heart attacks and strokes, which are among the leading causes of death worldwide. Drugs used to treat atherosclerosis are primarily aimed at reducing the underlying causes of the condition, such as high levels of cholesterol and triglycerides in the blood, and managing risk factors like high blood pressure. Statins are the most widely used class of drugs in this category and work by inhibiting the enzyme involved in cholesterol synthesis, thereby lowering cholesterol levels in the blood. Other drug classes include fibrates, niacin, bile acid sequestrants, and newer agents like PCSK9 inhibitors, which significantly reduce low-density lipoprotein (LDL) cholesterol and are particularly useful in patients with genetic lipid disorders or those who do not respond adequately to statins.

Recent advancements in the treatment of atherosclerosis focus on a more comprehensive approach to cardiovascular risk reduction, beyond merely managing cholesterol levels. This includes the development of drugs that target inflammatory processes which contribute to plaque build-up and instability. For instance, anti-inflammatory treatments such as canakinumab have shown potential in reducing the risk of cardiovascular events by targeting specific inflammatory pathways associated with atherosclerosis. Additionally, the integration of precision medicine into treatment protocols allows for tailored therapeutic strategies based on individual genetic profiles, improving the efficacy and safety of drug therapies. The advent of gene editing technologies and RNA therapies also holds promise in directly modifying the contributors to atherosclerosis at the molecular level, potentially offering more permanent solutions than traditional pharmaceutical approaches.

The growth in the atherosclerosis drugs market is driven by several factors, including the increasing prevalence of cardiovascular diseases globally, heightened awareness and proactive management of heart health among the general population, and significant advancements in drug research and development. An aging global population and lifestyle factors such as poor diet, lack of physical activity, and smoking contribute to the rising incidence of atherosclerosis and related cardiovascular conditions, fueling demand for effective treatments. The pharmaceutical industry`s commitment to innovation in this area is evidenced by substantial investments in R&D for developing more effective and safer therapies, with a particular emphasis on addressing drug resistance and reducing side effects associated with long-term use. Furthermore, government initiatives to reduce the burden of cardiovascular diseases through public health campaigns and supportive policies promote the use of preventive and therapeutic drugs. As patient education improves and screening becomes more widespread, the early adoption of drug therapies to manage risk factors effectively is expected to rise, further propelling market growth.

Select Competitors (Total 86 Featured) -

• AdvaCare Pharma
• Astrazeneca Pharmaceuticals LP
• Cayman Chemical Company
• Crescent Pharma Ltd
• Kowa Co., Ltd.
• Lupin Pharmaceuticals, Inc
• MilliporeSigma
• Novartis International AG
• Pfizer, Inc.
• Rosemont Pharmaceuticals Limited
• Sterling Biotech Ltd
• Teva Pharmaceuticals USA, Inc.
• Tokyo Chemical Industry Co., Ltd.
• Viatris, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.